Rep. Gilbert Ray Cisneros, Jr. Purchases AtriCure, Inc. (NASDAQ:ATRC) Shares

Posted by Kim Johansen on Sep 13th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in AtriCure stock on August 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

AtriCure Stock Performance

Shares of ATRC stock opened at $54.54 on Friday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $42.41 and a two-hundred day simple moving average of $33.55. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $55.72. The firm has a market capitalization of $2.77 billion, a PE ratio of 259.73 and a beta of 1.26.

AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at AtriCure

In other news, insider Salvatore Privitera sold 7,763 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the completion of the transaction, the insider directly owned 150,921 shares in the company, valued at $7,923,352.50. The trade was a 4.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl Dahlquist sold 9,370 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 65,036 shares of company stock worth $2,758,687. 4.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. BTIG Research raised their target price on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. UBS Group cut their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Piper Sandler upped their price target on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Check Out Our Latest Stock Analysis on ATRC

Institutional Trading of AtriCure

A number of institutional investors and hedge funds have recently modified their holdings of ATRC. Bank of America Corp DE boosted its position in shares of AtriCure by 13.7% in the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after acquiring an additional 92,830 shares during the period. Man Group plc bought a new stake in AtriCure during the 2nd quarter worth approximately $684,000. Assenagon Asset Management S.A. bought a new stake in AtriCure during the 2nd quarter worth approximately $1,744,000. Rice Hall James & Associates LLC purchased a new stake in AtriCure in the 2nd quarter worth approximately $3,755,000. Finally, California State Teachers Retirement System boosted its holdings in AtriCure by 33.3% in the 1st quarter. California State Teachers Retirement System now owns 59,947 shares of the medical device company’s stock valued at $1,710,000 after purchasing an additional 14,987 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

(Get Free Report)

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.